MAIA Biotechnology (MAIA) director reports stock purchase and new options

Rhea-AI Filing Summary

MAIA Biotechnology director reports stock and option purchases. A company director filed details of a recent transaction in MAIA Biotechnology, Inc. common stock. On December 22, 2025, the director purchased 40,849 shares of common stock at a price of $1.224 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. Following this transaction, the director beneficially owns 151,873 shares of MAIA common stock directly.

The director also acquired 40,849 stock options (treated as warrants under the same purchase agreement and plan) with an exercise price of $1.36 per share. These options become exercisable on June 22, 2026, which is six months after the issuance date, and are scheduled to expire on December 22, 2028.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHAOUKI STEVEN M

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/22/2025		P		40,849(1)	A	$1.224	151,873	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.36	12/22/2025		P		40,849(2)		06/22/2026	12/22/2028	Common Stock	40,849	$1.36	40,849	D

Explanation of Responses:

1. The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.

2. These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.

	/s/ Steven M. Chaouki	12/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA Biotechnology (MAIA) report?

A director of MAIA Biotechnology, Inc. reported buying 40,849 shares of common stock on December 22, 2025 and acquiring 40,849 stock options on the same date.

At what price did the MAIA Biotechnology director buy common shares?

The director purchased 40,849 MAIA common shares at a price of $1.224 per share pursuant to a Securities Purchase Agreement and the 2021 Equity Incentive Plan.

How many MAIA Biotechnology shares does the director own after the transaction?

After the reported transaction, the director beneficially owns 151,873 shares of MAIA Biotechnology common stock in direct ownership.

What are the key terms of the director’s MAIA stock options?

The director holds 40,849 stock options with an exercise price of $1.36 per share. The options become exercisable on June 22, 2026 and expire on December 22, 2028.

Under what plan were the MAIA shares and options issued to the director?

Both the purchased common stock and the stock options were issued under MAIA Biotechnology’s 2021 Equity Incentive Plan pursuant to a Securities Purchase Agreement.

What is the relationship of the reporting person to MAIA Biotechnology?

The reporting person is identified as a Director of MAIA Biotechnology, Inc., filing individually as one reporting person.